- Home
- NRXS vs APVO Comparison
NRXS vs APVO Comparison
Compare NRXS & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | APVO |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 21.7M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | NRXS | APVO |
|---|---|---|
| Price | $2.67 | $1.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 62.2K | ★ 633.3K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,362,320.00 | N/A |
| Revenue This Year | $31.05 | N/A |
| Revenue Next Year | $137.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.89 | N/A |
| 52 Week Low | $1.33 | $1.04 |
| 52 Week High | $6.20 | $298.00 |
Technical Indicators
Market Signals| Indicator | NRXS | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 48.61 |
| Support Level | $2.65 | $1.26 |
| Resistance Level | $2.82 | $1.41 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 74.21 | 80.52 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.